Adding ribociclib to endocrine therapy shows an improvement in invasive disease-free survival in HR+/HER2 BC patients
Adding ribociclib to endocrine therapy shows an improvement in invasive disease-free survival in HR+/HER2 BC patients
Nine-weeks trastuzumab still effective compared with one year trastuzumab for early-stage HER2 positive breast cancer
ATTRACTION-5: Nivolumab plus chemotherapy as postoperative adjuvant treatment for pStage III G/GEJ cancer
NSIA and Nigeria to improve treatment for Nigerians through the building of new cancer centres
NSIA and BVGH aim to improve patient outcomes and access to quality cancer care
Oncologic safety of breast conservation following NACT in women with locally advanced breast cancer
Maximising diagnosis of colon cancer with target screening
Optimising colon cancer care in Nigeria
Current MM diagnosis and treatment strategies
Optimising cervical cancer care in Nigeria
Tackling low-volumes of clinical trials in Africa
Low-cost detection and treatment strategies for breast cancer patients in LMICs